Navigation Links
Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
Date:3/14/2012

Recent breakthroughs in Chikungunya research spearheaded by scientists at A*STAR's Singapore Immunology Network (SIgN) have made great strides in the battle against the infectious disease. Working in close collaborations with Singapore clinician-scientists and international researchers , Dr Lisa Ng, Principal Investigator of the Chikungunya research group at SIgN, led the team to discover a direct biomarker which serves as an early and accurate prognosis of patients who have a higher risk of the more severe form of Chikungunya fever (CHIKF). This means that doctors can now quickly and accurately identify patients at risk, facilitating a more targetted treatment and clinical care at the onset of the disease.

Chikungunya fever, caused by the Chikungunya virus (CHIKV) , is a mosquito-borne, infectious disease endemic to Southeast Asia and Africa. Since its re-emergence in 2005, CHIKV infection has spread to nearly 20 countries to infect millions . Singapore, for instance, was hit twice by Chikungunya fever outbreaks in January and August 2008.

CHIKV infection is characterised by an abrupt onset of fever frequently accompanied by severe muscle and joint pains. Though most patients recover fully within a week, in severe cases, the joint pains may persist for months, or even years. For individuals with a weak immune system, the disease can result in death. With no clinically-approved vaccine or treatment for Chikungunya fever, it remains a worrying public health problem.

To devise strategies to stop CHIKV transmission, Dr Ng's team collaborated with Professor Leo Yee Sin and Dr Angela Chow, clinician-scientists from the Communicable Disease Centre (CDC) at Tan Tock Seng Hospital , to study how the human body responds to CHIKV infection. The team conducted a comprehensive study on the antibody response against CHIKV in patients. They discovered that patients who respond to the disease at the onset with high levels of Immunoglobulin G3 (IgG3), a naturally-acquired antibody, are protected from the more severe form of Chikungunya fever, characterised by persistent joint pains. On the other hand, patients with a delayed IgG3 response generally have less acute symptoms at the start, but are more susceptible to chronic debilitating joint pains at later stage of the disease. Hence, the IgG3 antibodies serve as a specific biomarker of patients with increased risk of the severe form of the disease.

Collaborating with computational experts from A*STAR's Institute for Infocomm Research (I2R), Dr Ng's team also uncovered that a very small defined segment of the Chikungunya viral protein, named "E2EP3", was able to induce the natural IgG3 protective response in preclinical models. They found that mice vaccinated with the E2EP3 peptides were protected against CHIKV with significant reduction in viral counts and joint inflammation. This finding raises hope for a new effective Chikungunya vaccine that can offer protection against Chikungunya virus in the event of an outbreak.

Dr Ng said, "Long-term treatment required for the chronic joint pain in Chikungunya-infected patients places social and economic burden for both patients and the public healthcare system. We are excited that the mechanistic insights gained through our collaborative research with the local hospitals and international research partners have led to discovery of 'new weapons' to tackle Chikungunya more effectively."

Scientific Director of SIgN, Professor Paola Castagnoli said, "With increasing threat of Chikungunya virus infection, particularly in Asia and the Pacific region, this significant breakthrough is a step forward in enhancing our pandemic preparedness against the infectious disease. This is a testament to the successful collaborations between research scientists and clinicians in translating scientific discoveries into impactful healthcare solutions for the benefit of Singapore and beyond. "


'/>"/>

Contact: Dr. Sarah Chang KC
chang_kai_chen@a-star.edu.sg
65-682-66442
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related biology news :

1. DOE researchers achieve important genetic breakthroughs to help develop cheaper biofuels
2. Argonne scientists awarded supercomputing time to enable scientific breakthroughs
3. IEEE-USA cites 5 engineering breakthroughs
4. Understanding global climate change through new breakthroughs in polar research
5. Bio-optics breakthroughs: Highlights of medical and bioscience research at Frontiers in Optics 2009
6. Key to future medical breakthroughs is systems biology, say leading European scientists
7. Experimental vaccine protects monkeys against chikungunya
8. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
9. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
10. A project to research biological and chemical aspects of microalgae to fuel approach
11. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology: